Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

185 Publicaciones científicas disponibles

  • Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma

    23 de abril de 2020 | Revista: Blood

    Perez C (1), Botta C (2), Zabaleta A (3), Puig N (4), Cedena MT (5), Goicoechea I (6), Alameda D (7), San-José Enériz E (8), Merino J (9), Rodriguez-Otero P (7), Maia CADS (6), Alignani D (10), Maiso P (7), Manrique I (11), Lara-Astiaso D (11), Vilas-Zornoza A (12), Sarvide S (13), Riillo C (14), Rossi M (14), Rosiñol L (15) Oriol A (16), Blanchard MJ (17), Rios R (18), Sureda A (19), Martín Sánchez J (20), Martinez R (21), Bargay J (22), de la Rubia J (23), Hernandez Garcia MT (24), Martínez-López J (5), Orfao A (25), Agirre X (26), Prosper F (7), Mateos MV (27), Lahuerta JJ (5), Bladé J (28), San Miguel J (26), Paiva B (7).

    (1) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA), Pamplona, Na, Spain.
    (2) "Annunziata" Hospital of Cosenza, Cosenza, Italy.
    (3) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain.
    (4) Hospital Universitario de Salamanca, Salamanca, Spain.
    (5) Hospital Universitario 12 de Octubre, Madrid, Spain.
    (6) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Pamplona, Spain.
    (7) Clinica Universidad de Navarra, Pamplona, Spain.
    (8) Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (9) University of Navarra, Pamplona, Spain.
    (10) Centro de Investigacion Medica Alplicada. Universidad de Navarra., Pamplona, Spain.
    (11) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
    (12) Centro de Investigacion Medica Aplicada, Pamplona, Spain.
    (13) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain, pamplona, Spain.
    (14) Magna Graecia University, Catanzaro, Italy.
    (15) Hospital Clínic, Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
    (16) ICO - Hosp Germans Trias i Pujol, Badalona, Spain.
    (17) Hospital Ramon y Cajal, madrid, Spain.
    (18) Hospital Universitario Virgen de las Nieves, Granada, Spain.
    (19) Institut Català d'Oncologia, Barcelona, Spain.
    (20) Hospital Universitario Virgen del Rocio, Sevilla, Spain.
    (21) Hospital Clinico San Carlos, Madrid, Spain.
    (22) Hospital Son LLatzer, Palma Mallorca, Spain.
    (23) School of Medicine and Dentistry, Catholic University of Valencia, Spain.
    (24) Hospital Universitario de Canarias, La Laguna. Tenerife, Spain.
    (25) University of Salamanca, Salamanca, Spain.
    (26) Universidad de Navarra, Pamplona, Spain.
    (27) University Hospital of Salamanca/IBSAL/Cancer Research Center, Salamanca, Spain.
    (28) Hospital Clínic i Provincial, Institut de Investicacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.


  • Epigenetic mechanisms and metabolic reprogramming in fibrogenesis

    23 de abril de 2020 | Revista: Gut

    Barcena-Varela M (1), Paish H (2), Alvarez L (1), Uriarte I (1,3), Latasa MU (1), Santamaria E (1,3), Recalde M (1), Garate M (1), Claveria A (1), Colyn L (1), Arechederra M (1), Iraburu MJ (4), Milkiewicz M (5), Milkiewicz P (6), Sangro B (3,7), Robinson SM (8), French J (8), Pardo-Saganta A (9,) Oyarzabal J (10), Prosper F (11), Rombouts K (12), Oakley F (2), Mann J (2), Berasain C (1,3), Avila MA (13,3), G Fernandez-Barrena M (14,15).

    (1) Hepatology Program, CIMA, University of Navarra, IdiSNA, Pamplona, Spain.
    (2) Newcastle Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK.
    (3) Clinica Universidad de Navarra, CIBERehd, Pamplona, Spain.
    (4) Department of Biochemistry and Genetics, University of Navarra, Pamplona, Navarra, Spain.
    (5) Department of Medical Biology, Pomeranian Medical University, Szczecin, Poland.
    (6) Department of General, Transplant and Liver Surgery, Warsaw Medical University, Szczecin, Poland.
    (7) Liver Unit. Department of Internal Medicine, Clinica Universidad de Navarra, IdisNA, Pamplona, Spain.
    (8) North East's Hepato-Pancreato-Biliary (HPB) Centre, Newcatle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
    (9) Cell Therapy Program, Cima, University of Navarra, Pamplona, Spain.
    (10) Molecular Therapies Program, Cima, University of Navarra, Pamplona, Spain.
    (11) Oncohematology and Cell Therapy Programs, CIMA, University of Navarra, IdiSNA, Pamplona, Spain.
    (12) Institute for Liver and Digestive Health, Royal Free, University College London, UCL, London, UK.
    (13) Hepatology Program, CIMA, University of Navarra, IdiSNA, Pamplona, Spain
    (14) CIBEREHD, Madrid, Spain
    (15) Hepatology Program, Centro de Investigacion Medica Aplicada, Pamplona, Navarra, Spain.


  • Biological and clinical significance of dysplastic hematopoiesis in patients with newly-diagnosed multiple myeloma

    16 de abril de 2020 | Revista: Blood

    Maia CADS (1), Puig N (2), Cedena MT (3), Goicoechea I (3), Valdés-Mas R (4), Vazquez I (5), Chillon MC (6), Aguirre P (1), Sarvide S (7), Gracia-Aznárez FJ (1), Alkorta-Aranburu G (1), Calasanz MJ (8), Garcia-Sanz R (6), González M (9), Gutierrez N (10), Martinez-Lopez J (3), Perez JJ (9), Merino J (8), Moreno C (8), Burgos L (8), Alignani D (11), Botta C (8), Prosper F (8), Matarraz S (12), Orfao A (13), Oriol A (14), Teruel AI (15), de Paz R (16), de Arriba F (17), Hernandez Garcia MT (18), Palomera L (19), Martinez R (20), Rosiñol L 21, Mateos MV (22), Lahuerta JJ (3), Bladé J (23), San Miguel J (8), Paiva B (24).

    (1) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Pamplona, Spain.
    (2) Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233 Salamanca, Spain.
    (3) CIBER-ONC number CB16/12/00369, Madrid, Spain.
    (4) DREAMgenics, Oviedo, Spain.
    (5) Universidad de Navarra, Pamplona, Spain.
    (6) Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233 Salamanca, Spain.
    (7) Centro de Investigacion Medica Aplicada, Pamplona, Spain.
    (8) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
    (9) Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233 Salamanca, Spain.
    (10) Instituto de Investigacion Biomedica de Salamanca,CIBER-ONC number CB16/12/00233 Salamanca (IBSAL),, Spain.
    (11) Clinica Universidad de Navarra,Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
    (12) Cytometry Service (NUCLEUS), and IBSAL. Cancer Research Center (IBMCC, University of Salamanca-CSIC), Salamanca, Spain.
    (13) Cancer Research Center (IBMCC-CSIC/USAL-IBSAL); Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca (USAL), CIBER-ONC number CB16/12/00400 Salamanca, Sri Lanka.
    (14) Institut Català d'Oncologia i Institut Josep Carreras, Badalona, Spain.
    (15) Hospital Clínico Universitario de Valencia.
    (16) Hospital Universitario La Paz, San sebastian de los Reyes, Spain.
    (17) Instituto Murciano de Investigación Biosanitaria (IMIB), Spain.
    (18) Hospital Universitario de Canarias, La Laguna. Tenerife, Spain.
    (19) Hospital Clínico, Zaragoza, Spain.
    (20) Hospital Clinico San Carlos, Madrid, Spain.
    (21) Hospital Clínic, Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
    (22) CIBER-ONC number CB16/12/00233 Salamanca, Spain.
    (23) Hospital Clínic i Provincial, Institut de Investicacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
    (24) Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.


  • Induction of Cyclooxygenase-2 by Overexpression of the Human NADPH Oxidase 5 (NOX5) Gene in Aortic Endothelial Cells

    6 de marzo de 2020 | Revista: Cells

    Marqués J (1,2), Cortés A (1,2), Pejenaute Á (1,2), Ansorena E (1,2), Abizanda G (2,3), Prósper F (2,3,4), Martínez-Irujo JJ (1,2), Miguel C (1,2), Zalba G (1,2).

    (1) Department of Biochemistry and Genetics, University of Navarra, 31008 Pamplona, Spain.
    (2) Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain.
    (3) Hematology Service, Clínica Universidad de Navarra, University of Navarra, 31008 Pamplona, Spain.
    (4) CIBERONC, 31008 Madrid, Spain.

No hay más publicaciones científicas

No hay más páginas para cargar